Insider · CIK 0001211701
M Kathleen Behrens
director
Files at SRPT (Sarepta Therapeutics, Inc.), MDXG (MIMEDX GROUP, INC.), IGMS (IGM Biosciences, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 18, 2025 | MDXG MIMEDX GROUP, INC. | AGrant or award Common Stock | +28,609 | $6.47 | $185k | 212,771 | Jun 23, 2025 |
| Mar 31, 2025 | IGMS IGM Biosciences, Inc. | AGrant or award Common Stock | +1,471 | $0.00 | $0 | 20,751 | Apr 2, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Common Stock | +2,383 | - | - | 193,476 | Mar 11, 2025 |
| Mar 10, 2025 | SRPT Sarepta Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +4,792 | $0.00 | $0 | 4,792 | Mar 11, 2025 |
| Dec 31, 2024 | IGMS IGM Biosciences, Inc. | AGrant or award Common Stock | +3,078 | $0.00 | $0 | 19,280 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.